How does the USPTO handle applications related to ‘recombinant DNA’ inventions?
How does the USPTO handle applications related to ‘recombinant DNA’ inventions?
The USPTO gives special attention to patent applications involving recombinant DNA inventions. According to MPEP 708:
“Applications relating to recombinant DNA have been accelerated by the Office under the Director’s Initiative.”
This means that:
- Recombinant DNA applications are prioritized for examination
- They are processed more quickly than standard applications
- This acceleration is part of a specific initiative by the USPTO Director
The special treatment of recombinant DNA applications reflects the importance and rapid development of biotechnology and genetic engineering fields. It allows for faster protection of potentially groundbreaking inventions in these areas.
To learn more: